Compugen Ltd (CGEN)

$1.65 +0.01 (0.61%)
Market Cap 146.35M
Revenue (ttm) 27.86M
Net Income (ttm) -14.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.08%
Debt to Equity Ratio 0.00
Volume 67,500
Avg Vol 258,616
Day's Range N/A - N/A
Shares Out 89.24M
Stochastic %K 18%
Beta 2.54
Analysts Strong Sell
Price Target $5.50

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 765 8585
Fax: 972 3 765 8555
Website: cgen.com
Address:
Azrieli Center, Building D 26 Harokmim Street, Holon, Israel
G101SPM
G101SPM Jun. 16 at 7:15 PM
#SHOWTIME ^European Association for Cancer Research Congress (June 17) Scheduled to appear: $CGEN, $PPBT ^ GE Aerospace Investor Day (June 17) Scheduled to appear: $GE ^ MercadoLibre, Inc. Annual General Meeting (June 17) Scheduled to appear: $MELI
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 13 at 1:48 PM
$CGEN when will this thing get out of the penalty box?
1 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 13 at 2:46 AM
$CGEN likely drop like a rock coming up. Ready to load more.
0 · Reply
That_Dude_Ober_Dare
That_Dude_Ober_Dare Jun. 6 at 4:05 PM
$CGEN is a real quiet winner with a +300% potential upside with a $6.00 1 year target price. Why is it so quiet?
2 · Reply
PenkeTrading
PenkeTrading Jun. 4 at 3:28 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Compugen. Is that bullish or bearish? $CGEN #Compugen #RsiOverbought #NASDAQ
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 4 at 3:12 AM
$MCTR keep this train rolling, moving to $CGEN $FATE
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 3 at 3:03 PM
$CGEN these bags are heavy and these pretzels are making me thirsty
0 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 3 at 2:43 PM
$CGEN If you wound up here compliments of the spike in share price and said “What’s CGEN?”….here you go: They are a BIO company with a solid pipeline, lots of cash, and lots of money coming in from Big Pharma partnerships with a whole bunch of trials going on. Oh yeah….and no debt. They are solid.
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 3 at 2:24 PM
$CGEN
0 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 3 at 2:18 PM
$CGEN Bump is compliments of AZN presentation at ASCO showing very positive results using CGEN’s creations. Pretty technical stuff being discussed but The Market is paying attention. Can’t imagine CGEN doesn’t get bought out at some level by Big Pharma.
2 · Reply
Latest News on CGEN
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Jun 12, 2025, 7:00 AM EDT - 5 days ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 10:21 AM EDT - 4 weeks ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

Compugen Reports First Quarter 2025 Results

May 19, 2025, 7:00 AM EDT - 4 weeks ago

Compugen Reports First Quarter 2025 Results

Compugen Announces Leadership Transitions Effective September 2025

May 13, 2025, 7:00 AM EDT - 5 weeks ago

Compugen Announces Leadership Transitions Effective September 2025

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

May 5, 2025, 7:00 AM EDT - 6 weeks ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 26, 2025, 7:00 AM EDT - 2 months ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 10:34 AM EST - 3 months ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 4, 2025, 7:00 AM EST - 3 months ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 3 months ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 26, 2025, 7:00 AM EST - 3 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 7:00 AM EST - 4 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 18, 2025, 6:11 AM EST - 4 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 4 months ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Jan 8, 2025, 7:00 AM EST - 5 months ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 27, 2024, 7:00 AM EST - 7 months ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:35 PM EST - 7 months ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Compugen Reports Third Quarter 2024 Results

Nov 12, 2024, 7:00 AM EST - 7 months ago

Compugen Reports Third Quarter 2024 Results

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 11, 2024, 7:00 AM EST - 7 months ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Nov 5, 2024, 9:00 AM EST - 7 months ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 29, 2024, 7:00 AM EDT - 8 months ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Present New Clinical Data at SITC 2024

Oct 7, 2024, 7:00 AM EDT - 9 months ago

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 10 months ago

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 7:00 AM EDT - 10 months ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 5:54 AM EDT - 11 months ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Compugen Reports Second Quarter 2024 Results

Aug 6, 2024, 7:00 AM EDT - 11 months ago

Compugen Reports Second Quarter 2024 Results

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 29, 2024, 7:00 AM EDT - 11 months ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jul 23, 2024, 7:00 AM EDT - 11 months ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Compugen to Present at Upcoming Antibody Industrial Symposium

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

Compugen Reports First Quarter 2024 Results

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Appoints David Silberman as Chief Financial Officer

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Compugen to Participate in Two Upcoming Investor Conferences

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Compugen to Participate in Two Upcoming Investor Conferences

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Mar 6, 2024, 7:00 AM EST - 1 year ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 2:41 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Compugen Reports Fourth Quarter and Full Year 2023 Results

Mar 5, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2023 Results

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 26, 2024, 7:00 AM EST - 1 year ago

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Feb 20, 2024, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Feb 15, 2024, 7:00 AM EST - 1 year ago

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY GSK ITOS MRK NVS PFE

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Jan 8, 2024, 7:05 AM EST - 1 year ago

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

AZN

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 7:00 AM EST - 1 year ago

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Compugen stock rockets on anti-tumor drug deal with Gilead

Dec 19, 2023, 7:13 AM EST - 1 year ago

Compugen stock rockets on anti-tumor drug deal with Gilead

GILD

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Dec 19, 2023, 7:10 AM EST - 1 year ago

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

AZN

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Dec 19, 2023, 7:05 AM EST - 1 year ago

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

G101SPM
G101SPM Jun. 16 at 7:15 PM
#SHOWTIME ^European Association for Cancer Research Congress (June 17) Scheduled to appear: $CGEN, $PPBT ^ GE Aerospace Investor Day (June 17) Scheduled to appear: $GE ^ MercadoLibre, Inc. Annual General Meeting (June 17) Scheduled to appear: $MELI
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 13 at 1:48 PM
$CGEN when will this thing get out of the penalty box?
1 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 13 at 2:46 AM
$CGEN likely drop like a rock coming up. Ready to load more.
0 · Reply
That_Dude_Ober_Dare
That_Dude_Ober_Dare Jun. 6 at 4:05 PM
$CGEN is a real quiet winner with a +300% potential upside with a $6.00 1 year target price. Why is it so quiet?
2 · Reply
PenkeTrading
PenkeTrading Jun. 4 at 3:28 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Compugen. Is that bullish or bearish? $CGEN #Compugen #RsiOverbought #NASDAQ
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 4 at 3:12 AM
$MCTR keep this train rolling, moving to $CGEN $FATE
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 3 at 3:03 PM
$CGEN these bags are heavy and these pretzels are making me thirsty
0 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 3 at 2:43 PM
$CGEN If you wound up here compliments of the spike in share price and said “What’s CGEN?”….here you go: They are a BIO company with a solid pipeline, lots of cash, and lots of money coming in from Big Pharma partnerships with a whole bunch of trials going on. Oh yeah….and no debt. They are solid.
0 · Reply
wenmoon_stonks
wenmoon_stonks Jun. 3 at 2:24 PM
$CGEN
0 · Reply
HuntingBenjmins
HuntingBenjmins Jun. 3 at 2:18 PM
$CGEN Bump is compliments of AZN presentation at ASCO showing very positive results using CGEN’s creations. Pretty technical stuff being discussed but The Market is paying attention. Can’t imagine CGEN doesn’t get bought out at some level by Big Pharma.
2 · Reply
HuntingBenjmins
HuntingBenjmins May. 31 at 5:12 AM
$CGEN If a ceasefire sticks we’ll see some movement.
0 · Reply
HuntingBenjmins
HuntingBenjmins May. 24 at 2:29 AM
$CGEN This saw the bump (and might continue) due to a few ASCO abstracts showing Compugen’s creations getting it done. Here’s a snippet from one of them and my understanding is that these are pretty promising numbers.
0 · Reply
HuntingBenjmins
HuntingBenjmins May. 22 at 7:50 PM
$CGEN
0 · Reply
Everest17
Everest17 May. 21 at 4:38 PM
$CGEN I’m back in. LFG!!!!!!
0 · Reply
bubbap
bubbap May. 20 at 1:45 AM
$CGEN hi guys, heard about compugen through a friend! I am curious as to what the company does and whats your guys bull case! Any literature i could read! Thanks guys
2 · Reply
Otus
Otus May. 19 at 2:41 PM
$CGEN yawn.
0 · Reply
mikesterz7
mikesterz7 May. 19 at 11:41 AM
$CGEN Compugen reported its Q1 2025 financial results and corporate updates. The company initiated a platform trial of COM701 maintenance therapy for platinum-sensitive ovarian cancer patients and continues recruitment for GS-0321 Phase 1 trial. Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across various cancers. Financially, Compugen reported $103.7 million in cash with runway into 2027, $2.3 million in revenues, and a net loss of $7.2 million ($0.08 per share) for Q1 2025. The company announced key leadership changes effective September 2025, with current CEO Dr. Anat Cohen-Dayag becoming Executive Chair and CSO Dr. Eran Ophir assuming the CEO position.
1 · Reply
Estimize
Estimize May. 19 at 10:00 AM
$CGEN reported - EPS and - revenue for Q1. http://www.estimize.com/intro/cgen?chart=historical&metric_name=eps&utm_content=CGEN&utm_medium=
0 · Reply
jdlman
jdlman May. 18 at 8:32 PM
$CGEN when is earnings?
0 · Reply
wenmoon_stonks
wenmoon_stonks May. 16 at 4:30 PM
$CGEN any update on the Gilead partnership?
0 · Reply
Otus
Otus May. 13 at 4:04 PM
$CGEN so far the market seems to be in favor of the management changes. Strong buy!!
0 · Reply
Otus
Otus May. 13 at 1:12 PM
$CGEN good riddance Anat! While she’s not completely going away at least we have a new hand running the day to day. Unfortunately another scientist and not a business person. I’m pretty certain she will be more involved as chairman and certainly more involved than the absentee chairman she is replacing. Net net I see this as good for the company.
0 · Reply